We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.72B
1-Year Est. Return 106.92%
This Fund
S&P 500
This Quarter Est. Return
+3.13%
1 Year Est. Return
+106.92%
3 Year Est. Return
+205.04%
5 Year Est. Return
+179.05%
10 Year Est. Return
+1,028.38%
AUM
$1.45B
AUM Growth
-$170M
Cap. Flow
+$90.1M
Cap. Flow %
6.21%
Top 10 Hldgs %
63.01%
Holding
41
New
5
Increased
1
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
EPC icon
Edgewell Personal Care
EPC
+$239M
2
AVBP icon
ArriVent BioPharma
AVBP
+$21.7M
3
VRDN icon
Viridian Therapeutics
VRDN
+$21.3M
4
MGX icon
Metagenomi Therapeutics
MGX
+$20M
5
KYTX icon
Kyverna Therapeutics
KYTX
+$19.5M

Top Sells

Rank Stock Value
1
TSM icon
TSMC
TSM
+$73.9M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$66.4M
3
CBAY
Cymabay Therapeutics
CBAY
+$21.3M
4
SPRB
Spruce Biosciences
SPRB
+$19.7M
5
CRM icon
Salesforce
CRM
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 45.12%
2 Technology 24.54%
3 Financials 13.03%
4 Consumer Staples 7.98%
5 Communication Services 3.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASML icon
1
ASML
ASML
$615B
$177M 12.22%
182,536
-15,224
-8% -$13.5M
BN icon
2
Brookfield
BN
$82.7B
$162M 11.21%
5,820,345
– –
CRM icon
3
Salesforce
CRM
$206B
$145M 9.98%
480,160
-50,340
-9% -$14.5M
EPC icon
4
Edgewell Personal Care
EPC
$1.23B
$116M 7.98%
+6,344,430
New +$239M
CORT icon
5
Corcept Therapeutics
CORT
$12.1B
$60.7M 4.19%
2,411,362
– –
PCVX icon
6
Vaxcyte
PCVX
$8.75B
$57.7M 3.98%
845,000
– –
CRNX
7
DELISTED
Crinetics Pharmaceuticals
CRNX
$51.4M 3.55%
1,098,600
-1,400
-0.1% -$54.8K
CABO icon
8
Cable One
CABO
$107M
$50.1M 3.46%
118,403
– –
LNZA icon
9
LanzaTech
LNZA
$77.5M
$48.9M 3.38%
158,148
– –
FDMT icon
10
4D Molecular Therapeutics
FDMT
$760M
$44.6M 3.08%
1,400,000
-100,000
-7% -$2.55M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.5B
$39.3M 2.71%
450,000
– –
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.32B
$37.7M 2.6%
1,500,000
– –
INSM icon
13
Insmed
INSM
$26.8B
$36.3M 2.51%
1,339,304
– –
BABA icon
14
Alibaba
BABA
$267B
$36.2M 2.5%
500,827
– –
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$34M 2.35%
358,626
-500
-0.1% -$42.9K
AAPL icon
16
Apple
AAPL
$4.85T
$31.4M 2.16%
182,960
-38,500
-17% -$7M
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$29.4M 2.03%
2,500,000
– –
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$382M
$28.3M 1.95%
1,050,000
– –
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
$27.9M 1.92%
1,250,000
– –
PHVS icon
20
Pharvaris
PHVS
$2.64B
$27M 1.86%
1,168,030
-371,295
-24% -$9.86M
VERV
21
DELISTED
Verve Therapeutics
VERV
$26.6M 1.83%
2,000,000
– –
BAM icon
22
Brookfield Asset Management
BAM
$72.2B
$26.4M 1.82%
627,207
– –
LXEO icon
23
Lexeo Therapeutics
LXEO
$341M
$25.7M 1.77%
1,638,298
+330,469
+25% +$5.17M
VRDN icon
24
Viridian Therapeutics
VRDN
$2.54B
$19.3M 1.33%
+1,100,000
New +$21.3M
AVBP icon
25
ArriVent BioPharma
AVBP
$1.36B
$19.2M 1.33%
+1,077,140
New +$21.7M
1
2

Similar funds

SIM
SSI Investment Management Los Angeles, California $1.72B AUM 7.09% 1-Year Est. Return
FDCP
Foster Dykema Cabot & Partners Waltham, Massachusetts $1.72B AUM 20.41% 1-Year Est. Return
HR
Howe & Rusling Rochester, New York $1.72B AUM 25.63% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
PIMG
Patriot Investment Management Group Knoxville, Tennessee $1.72B AUM 17.84% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
FMLI
Fukoku Mutual Life Insurance Tokyo, Japan $1.72B AUM 29.29% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Novo Holdings A/S's Q1 2024 Portfolio in Review

As of Q1 2024, Novo Holdings A/S held 41 positions worth $1.45B, down 10% from $1.62B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Novo Holdings A/S deployed $90.1M of net new capital in Q1 2024, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Edgewell Personal Care: 6,344,430 shares worth $116M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 52% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Salesforce, an estimated $14.5M trimmed.

  • Novo Holdings A/S's largest Q1 2024 buy was Edgewell Personal Care: 6,344,430 shares worth $116M.
  • Novo Holdings A/S added most to Lexeo Therapeutics in Q1 2024, an estimated $5.17M increase.
  • Novo Holdings A/S's biggest Q1 2024 reduction was Salesforce, cutting an estimated $14.5M.
  • Novo Holdings A/S fully exited TSMC in Q1 2024, selling an estimated $73.9M.
  • Novo Holdings A/S's ten largest holdings make up 63% of its $1.45B portfolio in Q1 2024.
  • Novo Holdings A/S opened 5 new positions and closed 6 in Q1 2024.
  • Novo Holdings A/S's portfolio value fell 10% quarter-over-quarter to $1.45B.

Based on Novo Holdings A/S's 13F filing for Q1 2024, filed 15 May 2024.